Clinical

Phase II results for sustained release ranibizumab treatment of AMD indicate patients may only require two ophthalmic visits per year

Anti-VEGF treatment of exudative age-related macular degeneration has represented a paradigm shift in the medical management of the disease however, not all patients obtain the… Read More »Phase II results for sustained release ranibizumab treatment of AMD indicate patients may only require two ophthalmic visits per year